A small pharma company best known for a malaria drug is now staking intellectual property on a tree seed, and the regulatory friction it just encountered tells you exactly how uncertain this pivot is. 60 Degrees Pharmaceuticals, whose ARAKODA tafenoquine product earned FDA approval in 2018, has signed an exclusive patent license with Florida State University covering large-scale extraction and purification of castanospermine from the seeds of Castanospermum australe, the Australian Chestnut, for non-prescription uses. The license matters because it secures the production rights needed to move from botanical curiosity to commercial supplement. What complicates the picture is that FDA has already issued a Non-Notification Letter in response to the company’s New Dietary Ingredient Notification, a formal signal that the submission did not satisfy the evidentiary threshold on safety before the company can legally market the ingredient in the U.S.
A Non-Notification Letter is not a rejection, but it is not a green light either. The agency has flagged that the current NDIN lacks sufficient “other safety information” to establish the safety of the proposed use, and 60 Degrees has scheduled a July 1 meeting with FDA to work through what additional evidence is required before a revised filing. That sequencing is worth noting: the company locked in the FSU license before resolving the regulatory question, a calculated move that secures supply-chain and IP position while the safety dossier is still being built. Castanospermine at low doses is documented in scientific literature to modulate carbohydrate metabolism, affecting glycogen and glucose markers, and animal studies at higher doses suggest immunomodulatory effects across several therapeutic areas. Neither profile is fully characterized for a finished supplement product, which is precisely why FDA pressed for more.
The commercial logic points toward a global botanical supplements market valued at $38.24 billion in 2024 and projected to reach $67.01 billion by 2030. For a company with going-concern language in its most recent 10-K and no manufacturing capacity of its own, capturing even a thin slice of that market with a proprietary extract backed by an exclusive university patent license would represent a meaningful revenue diversification away from a single approved pharmaceutical product. The FSU deal provides the extraction and purification methodology at scale, which resolves one dependency. FDA remains the other.
The outcome of the July 1 meeting will determine whether this botanical bet accelerates or stalls. Watch the revised NDIN submission date: a rapid turnaround would signal that FDA’s safety concerns are narrow and addressable, while a prolonged gap between the meeting and resubmission would indicate the evidentiary bar is more demanding than the company currently telegraphs.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
